Xenogeneic transplantation

British Medical Bulletin

Volumn 53, Issue 4, 1997, Pages 904-920

  Van Den Bogaerde, Johan ^a   White, David J G ^a  

^a Imutran Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR;

CELL STRUCTURE; COMPLEMENT ACTIVATION; GRAFT REJECTION; PRIORITY JOURNAL; REVIEW; SWINE; XENOGRAFT; XENOTRANSPLANTATION;

EID: 0030829664     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.bmb.a011658     Document Type: Review

References (77)

1. Calne RY. Organ transplantation between widely disparate species. Transplant Proc 1970; 2: 550-6
2. Auchincloss Jr H. Xenogeneic transplantation. A review. Transplantation 1988; 46: 1-20
3. Gore SM, Cable DJ, Holland AJ. Organ donation from intensive care units in England and Wales: two year confidential audit of deaths in intensive care [see comments]. BMJ 1992; 304: 349-55
4. Organ Shortage: The Solutions. Dordrecht: Kluwer, 1995
5. Murphy B, Auchincloss Jr H, Carpenter CB, Sayegh MH. T cell recognition of xeno-MHC peptides during concordant xenograft rejection. Transplantation 1996; 61: 1133-7
6. Van den Bogaerde JB, Aspinall R, White DJ. Hamster to rat xenografts are not rejected primarily by rat T cells. Transplant Proc 1991; 23: 2277-9
7. Hasan RI, van den Bogaerde J, Forty J, Wright L, Wallwork J, White DJ. Prolonged survival of hamster to rat heart xenografts with cyclophosphamide therapy. Transplant Proc 1992; 24: 517-8
8. van den Bogaerde J, Aspinall R, Wang MW et al. Induction of long-term survival of hamster heart xenografts in rats. Transplantation 1991; 52: 15-20
9. Reemtsma K. Heterotransplantation: theoretical considerations. Transplant Proc 1971; 3: 49-52
10. Reemtsma K. Heterotransplantation. Transplant Proc 1969; 1: 251-5
11. Reemtsma K. Renal heterotransplantation. Adv Surg 1966; 2: 285-93
12. Reemtsma K, McCracken BH, Schlegel JU et al. Ann Surg 1964; 160: 384-410
13. Bailey LL, Nehlsen Cannarella SL, Concepcion W, Jolley WB. Baboon-to-human cardiac xenotransplantation in a neonate. JAMA 1985; 254: 3321-9
14. Chiche L, Adam R, Caillat Zucman S, Castaing D, Bach JF, Bismuth H. Xenotransplantation: baboons as potential liver donors? Scientific and ethical issues. Transplantation 1993; 55: 1418-21
15. Pierson 3rd RN, White DJ, Wallwork J. Ethical considerations in clinical cardiac xenografting [letter]. J Heart Lung Transplant 1993; 12: 876-8
16. Department of Health. Animal Tissue into Humans. A report by the advisory group on the ethics of xenotransplantation. London: HMSO, 1996
17. Arther J, Noakes D, Pearson H. Eds. Veterinary Reproduction and Obstetrics, 6th edn. London: 1983; 49-161
18. Platt JL, Holzknecht ZE, Lindman BJ. Porcine endothelial cell antigens recognized by human natural antibodies. Transplant Proc 1994; 26: 1387
19. Platt JL, Lindman BJ, Geller RL et al. The role of natural antibodies in the activation of xenogenic endothelial cells. Transplantation 1991; 52: 1037-43
20. Hammer C, Chaussy C, Brendel W. Preformed natural antibodies in animals and man. Outlook on xenotransplantation. Eur Surg Res 1973; 5: 162-6
21. Blakely ML, Van der Werf WJ, Berndt MC, Dalmasso AP, Bach FH, Hancock WW. Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection. Transplantation 1994; 58: 1059-66
22. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214-20
23. Sandrin MS, McKenzie IF. Gal alpha (l,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies. Immunol Rev 1994; 141: 169-90
24. Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans [see comments]. Immunol Today 1993; 14: 480-2
25. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IF. Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391-5
26. Oriol R, Ye Y, Koren E, Cooper DK. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation. Transplantation 1993; 56: 1433-42
27. Platt JL, Lindman BJ, Chen H, Spitalnik SL, Bach FH. Endothelial cell antigens recognized by xenoreactive human natural antibodies. Transplantation 1990; 50: 817-22
28. Holzknecht ZE, Platt JL. Identification of porcine endothelial cell membrane antigens recognized by human xenoreactive natural antibodies. J Immunol 1995; 154: 4565-75
29. Galili U, Rachmilewitz EA, Peleg A, Flechner I. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med 1984; 160: 1519-31
30. Cairns T, Karlsson E, Holgersson J, Taube D, Welsh K, Samuelsson G. Confirmation of a major target epitope of human natural IgG and IgM anti-pig antibodies: terminal galactose alpha-1,3-galactose. Transplant Proc 1994; 26: 1384
31. Latinne D, Soares M, Havaux X et al. Depletion of IgM xenoreactive natural antibodies by injection of anti-mu monoclonal antibodies. Immunol Rev 1994; 141: 95-125
32. Soares M, Lu X, Havaux X et al. In vivo IgM depletion by anti-mu monoclonal antibody therapy. The role of IgM in hyperacute vascular rejection of discordant xenografts. Transplantation 1994; 57: 1003-9
33. Pruitt SK, Baldwin 3rd WM, Barth RN, Sanfilippo F. The effect of xenoreactive antibody and B cell depletion on hyperacute rejection of guinea pig-to-rat cardiac xenografts. Transplantation 1993; 56: 1318-24
34. Leventhal J, John R, Fryer JP et al. Removal of baboon and human anti-porcine IgG and IgM natural antibodies by immmunoabsorption. Transplantation 1995; 59: 294-300
35. Forty J, Hasan R, Cary N, White DJ, Wallwork J. Hyperacute rejection of rabbit hearts by human blood is mediated by the alternative pathway of complement. Transplant Proc 1992; 24: 488-9
36. Hammer C, Suckfull M, Saumweber D. Evolutionary and immunological aspects of xenotransplantation. Transplant Proc 1992; 24: 2397-400
37. Koike C, Hayashi S, Yokoyama I, Yamakawa H, Negita M, Takagi H. Converting alpha-Gal epitope of pig into H antigen. Transplant Proc 1996; 28: 553
38. Atkinson JP, Oglesby TJ, White D, Adams EA, Liszewski MK. Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor. Clin Exp Immunol 1991; 86 Suppl 1: 27-30
39. O'Regan CC, Robitaille P, Pinto Blonde M, Chartrand C. Delayed rejection of cardiac xenografts in C6-deficient rabbits. Immunology 1979; 38: 245-8
40. Brauer RB, Baldwin 3rd WM, Daha MR, Pruitt SK, Sanfilippo F. Use of C6-deficient rats to evaluate the mechanism of hyperacute rejection of discordant cardiac xenografts. J Immunol 1993; 151: 7240-8
41. Leventhal JR, Dalmasso AP, Cromwell JW et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857-65
42. Post TW, Arce MA, Liszewski MK, Thompson ES, Atkinson JP, Lublin DM. Structure of the gene for human complement protein decay accelerating factor. J Immunol 1990; 144: 740-4
43. Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 1991; 9: 431-55
44. Hourcade D, Garcia AD, Post TW et al. Analysis of the human regulators of complement activation (RCA) gene cluster with yeast artificial chromosomes (YACs). Genomics 1992; 12: 289-300
45. Kinoshita T. Biology of complement: the overture. Immunol Today 1991; 12: 291-5
46. Davies KA. Complement. Baillière's Clin Haematol 1991; 4: 927-55
47. Morgan BP. Complement regulatory molecules: application to therapy and transplantation. Immunol Today 1995; 16: 257-9
48. Morgan BP, Meri S. The biology of complement: membrane proteins that protect against complement lysis. Springer Semin lmmunopathol 1994; 15: 48-59
49. Nickells MW, Alvarez JI, Lublin DM, Atkinson JP. Characterization of DAF-2, a high molecular weight form of decay-accelerating factor (DAF; CD55), as a covalently cross-linked dimer of DAF-1. J Immunol 1994; 152: 676-85
50. White D, Langford G, Cozzi E, Young V. Production of pigs transgenic for human DAF: a strategy for xenotransplantation. Xenotransplantation 1995; &B2: 213-7
51. Carrington CA, Richards AC, Cozzi E, Langford G, Yannoutsos N, White DJ. Expression of human DAF and MCP on pig endothelial cells protects from human complement. Transplant Proc 1995; 27: 321-3
52. Miyagawa S, Shirakura R, Iwata K et al. Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAE hybrid, on complement-mediated swine endothelial cell lysis. Transplantation 1994; 58: 834-40
53. White D. Alteration of complement activity: a strategy for xenotransplantation. Trends Biotechnol 1996; 14: 3-5
54. White DJ, Cozzi E, Langford G et al. Genetic engineering of the donor species to control hyperacute xenograft rejection. Adv Nephrol Necker Hasp 1995; 24: 331-40
55. White DJ, Cozzi E, Langford G et al. The control of hyperacute rejection by genetic engineering of the donor species. Eye 1995; 9: 185-9
56. White DJ, Oglesby T, Liszewski MK et al. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transplant Proc 1992; 24: 474-6
57. Vercellotti GM, Platt JL, Bach FH, Dalmasso AP. Neutrophil adhesion to xenogeneic endothelium via iC3b. J Immunol 1991; 146: 730-4
58. Brinster RL, Allen JM, Behringer RR, Gelinas RE, Palmiter RD. Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sci USA 1988; 85: 836-40
59. Pursel VG, Bolt DJ, Miller KF et al. Expression and performance in transgenic pigs. J Reprod Fertil Suppl 1990; 40: 235-45
60. Russell SM, Sparrow RL, McKenzie IF, Purcell DF. Tissue-specific and allelic expression of the complement regulator CD46 is controlled by alternative splicing. Eur J Immunol 1992; 22: 1513-8
61. Yannoutsos N, Ijzermans JNM, White D. Using yeast artificial chromosomes to generate transgenic animals. Xeno 1995; 3: 107-9
62. Rosengard A, Cary N, Langford G, Tucker A, Wallwork J, White D. Tissue expression on human complement inhibitor, decay-accelerating factor, in transgenic pig. Transplantation 1995; 59: 1325-33
63. Cozzi E, Langford GA, Wright L et al. Longitudinal analysis of the expression of human decay accelerating factor on peripheral blood mononuclear cells and in the plasma of transgenic pigs. Transplant Proc 1996; 28: 860-1
64. Cozzi E, Langford GA, Wright L et al. Comparative analysis of human DAF expression in the tissues of transgenic pigs and man. Transplant Proc 1995; 27: 319-20
65. Fearon DT, Collins BH. Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotaxic factors and purification procedures. J Immunol 1983; 130: 370-5
66. Young V. Studies of hyperacute xenograft rejection using an ex vivo model. MD Thesis 1995; Trinity College
67. White D. hDAF transgenic pig organs: are they concordant for human transplantation. Xeno 1996; 4: 50-4
68. Pruitt SK, Kirk AD, Bollinger RR et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994; 57: 363-70
69. van den Berg CW, Morgan BP. Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted. J Immunol 1994; 152: 4095-101
70. Byrne GW. Transgenic pigs.... Transplantation 1997; 63: 149-55
71. Yasunga C, Cramer DV, Cozenza CA et al. Effect of brequinar sodium on in vivo antibody production. Transplant Proc 1993; 25: 40-4
72. Morikwa K, Oseko F, Morikwa S. The suppressive effects of deoxyspergualin on the differentiation of human B lymphocytes maturing into immunoglobulin producing cells. Transplantation 1992; 54: 526-31
73. Ulrichs K, Katitchick J, Bartlett R, Muller-Ruchholz W. Suppression of natural xenophile antibodies with the novel immunomodulating drug leflunomide. Transplant Proc 1992; 24: 718-9
74. Segal SN. Rapamune (Rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660-5
75. Auchincloss Jr H. Cell-mediated xenoresponses: strong or weak? Clin Transplant 1994; 8: 155-9
76. Wrighton CJ, Hofer Warbinek R, Moll T, Eytner R, Bach FH, de Martin R. Inhibition of endothelial cell activation by adenovirus-mediated expression of IkappaBalpha, an inhibitor of the transcription factor NF-kappaB. J Exp Med 1996; 183: 1013-22
77. d'Apice AJ, Tange MJ, Chen GC, Cowan PJ, Shinkel TA, Pearse MJ. Two genetic approaches to the galactose alpha 1,3 galactose xenoantigen. Transplant Proc 1996; 28: 540